Prot #CLCZ696D2301: A Multicenter, Randomized, Double-blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) with Preserve

Project: Research project

Project Details

StatusActive
Effective start/end date8/1/138/31/21

Funding

  • Novartis Pharmaceuticals Corporation (CLCZ696D2301)